Zusammenfassung
Das höchste Verordnungsvolumen der Onkologika haben Hormonantagonisten zur Behandlung des Mammakarzinoms und des Prostatakarzinoms, auf die fast 70% der definierten Tagesdosen (DDD) entfallen. An zweiter Stelle stehen die klassischen Zytostatika mit der führenden Gruppe der Antimetabolite, was vor allem auf den häufigen Verordnungen von 5-Fluorouracil beruht. Als nächste Gruppen folgen mit deutlichem Abstand monoklonale Antikörper und Proteinkinaseinhibitoren. Führende Gruppen der monoklonalen Antikörper sind weiterhin die HER2-Antikörper zur Behandlung des HER2-positiven Mammakarzinoms gefolgt von Antikörpern gegen VEGF, CD20 und PD-1-Rezeptoren, die für ein wachsendes Spektrum von onkologischen Indikationen indiziert sind. Führender Vertreter der Proteinkinaseinhibitoren ist weiterhin Imatinib, der erfolgreiche Standard für die Behandlung der Philadelphia-Chromosom-positiven chronischen myeloischen Leukämie. Weitere Proteinkinaseinhibitoren werden vor allem zur Behandlung der chronischen lymphatischen Leukämie, der primären Myelofibrose, des nicht-kleinzelligen Lungenkarzinoms, des Nierenzellkarzinoms, des Melanoms, des kolorektalen Karzinoms und des Mammakarzinoms eingesetzt.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Adams JL, Smothers J, Srinivasan R, Hoos A (2015): Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov 14: 603–622
Al-Lazikani B, Banerji U, Workman P (2012): Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 30: 679–692
André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A (2009): Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27: 3109–3116
Apperley JF (2015): Chronic myeloid leukaemia. Lancet 385: 1447–1459
Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG, de Bono JS (2016): Prostate cancer. Lancet 387: 70–82
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013): European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122: 872–884
Barbui T, Finazzi MC, Finazzi G (2012): Front-line therapy in polycythemia vera and essential thrombocythemia. Blood Rev 26: 205–211
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators (2014): Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371: 424–433
Beyer J, Albers P, Altena R, Aparicio J et al (2013): Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 24: 878–888
Bundesministerium für Gesundheit (2014): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V), Ruxolitinib vom 6. November 2014, veröffentlicht Montag, 15. Dezember 2014, BAnz AT 15.12.2014 B4
Bundesministerium für Gesundheit (2015): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Eribulin (neues Anwendungsgebiet) vom 22. Januar 2015, veröffentlicht am Montag, 16. Februar 2015 BAnz AT 16.02.2015 B3 Seite 1 von 9
Bundesministerium für Gesundheit (2016a): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Elotuzumab vom 1. Dezember veröffentlicht am Mittwoch, 28. Dezember 2016 BAnz AT 28.12.2016 B2 Seite 1 von 6
Bundesministerium für Gesundheit (2016b): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Crizotinib (neues Anwendungsgebiet) vom 16. Juni 2016 veröffentlicht am Dienstag, 20. September 2016 BAnz AT 20.09.2016 B2
Bundesministerium für Gesundheit (2016c): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Ramucirumab (neues Anwendungsgebiet) vom 1. September 2016, veröffentlicht am Donnerstag, 22. September 2016 BAnz AT 22.09.2016 B3 Seite 1 von 4
Bundesministerium für Gesundheit (2016d): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Ramucirumab (neues Anwendungsgebiet) vom 1. September 2016, veröffentlicht am Freitag, 16. September 2016 BAnz AT 16.09.2016 B1 Seite 1 von 6
Bundesministerium für Gesundheit (2018a): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Carfilzomib (Neubewertung eines Orphan Drugs nach on Arzneimitteln mit neuen Wirkstoffen nach Vom 15. Februar 2018, Veröffentlicht am Freitag, 9. März 2018 BAnz AT 09.03.2018 B2 Seite 1 von 10
Bundesministerium für Gesundheit (2018b): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Daratumumab (neues Anwendungsgebiet; Neubewertung eines Orphan Drugs nach en rschreitung der 50-Millionen-Euro-Grenze) vom 15. Februar 2018, veröffentlicht am Donnerstag, 15. März 2018 BAnz AT 15.03.2018 B3
Byrd JC, Brown JR, O‹Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators (2014a): Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371: 213–223
Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM (2014b): Entering the era of targeted therapy for chronic lymphocytic leukemia: Impact on the practicing clinician. J Clin Oncol 32: 3039–3047
Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team (2017): 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389: 1195–1205
Cervantes F (2014): How I treat myelofibrosis. Blood 124: 2635–2642
Cheson BD, Leonard JP (2008): Monoclonal antibody therapy for B-cell non-Hodgkin‹s lymphoma. N Engl J Med 359: 613–626
Cheson BD, Rummel MJ (2009): Bendamustine: rebirth of an old drug. J Clin Oncol 27: 1492–1501
Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X (2015): New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci 36: 587–595
Choueiri TK, Motzer RJ (2017): Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 376: 354–366
Ciardiello F, Tortora G (2008): EGFR antagonists in cancer treatment. N Engl J Med 358: 1160–1174
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002): CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235–242
Collins FS, Varmus H (2015): A new initiative on precision medicine. N Engl J Med 372: 793–795
Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389) investigators (2011): Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377: 914–923
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al. (2004): A randomised comparison of cetuximab monotherapy and cetuximab plus Irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF; ATAC/LATTE investigators (2010): Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11: 1135–1141
De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators (2010): Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376: 1147–1154
Deutsche Krebsgesellschaft e.V., Deutschen Krebshilfe, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (Hrsg) (2016): Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. Langversion 4.0 – Dezember 2016, AWMF-Register-Nummer 043/022OL. Federführende Fachgesellschaft Deutsche Gesellschaft für Urologie e. V. (DGU). Internet: http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/
Deutsche Krebsgesellschaft e.V., Deutschen Krebshilfe, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (Hrsg) (2017): Konsultationsfassung S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms Langversion 0.4.0 – Juni 2017, AWMF-Registernummer: 032-045OL Federführende Fachgesellschaften Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG), Deutsche Krebsgesellschaft (DKG): Internet: http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/
DeVita VT, Rosenberg SA (2012): Two hundred years of cancer research. N Engl J Med 366: 2207–2214
Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Malorni L, Garnett S, Rukazenkov Y, Martin M (2014): Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 106: djt337
Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P (2017a): Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 18: 1327–1337
Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P (2017b): Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol 178: 896–905
Dobbelstein M, Moll U (2014): Targeting tumour-supportive cellular machineries in anticancer drug development. Nat Rev Drug Discov 13: 179–196
Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J (2010): Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697–4705
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687–1717
Eichhorst B, Hallek M (2016): Neue Therapiekonzepte bei der chronisch-lymphatischen Leukämie. Onkologe 22: 283–294
Ellis MJ, Llombart-Cussac A, Feltl D, Dewar JA, Jasiówka M, Hewson N, Rukazenkov Y, Robertson JF (2015): Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: Overall survival analysis from the phase II FIRST study. J Clin Oncol 33: 3781–3787
Ernst E, Schmidt K, Steuer-Vogt MK (2003): Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer 107: 262–267
European Medicines Agency (2016): CHMP confirms recommendations for use of Zydelig. Patients should be monitored for infection and given antibiotics during and after treatment. 22 July 2016 EMA/488322/2016. Internet: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/07/news_detail_002573.jsp&mid=WC0b01ac058001d126
Evans JB, Syed BA (2014): From the analyst‹s couch: Nextgeneration antibodies. Nat Rev Drug Discov 13: 413–414
Falchi L, Bose P, Newberry KJ, Verstovsek S (2017): Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment? Br J Haematol 176: 352–364
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group (2009): Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10: 223–232
Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ (2016): Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375: 1925–1936
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN; LATITUDE Investigators (2017): Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 377: 352–360
Foà R (2014): Changes in the treatment landscape for chronic lymphoid leukemia. N Engl J Med 371: 273–274
Food and Drug Administration (2011): FDA Commissioner removes breast cancer indication from avastin label. Internet: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm279485.htm
Fruman DA, Rommel C (2014): PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13: 140–156
Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O’Brien SM (2014): Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370: 997–1007
Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S (2016): Diagnostik und Therapie des Multiplen Myeloms. Dtsch Ärztebl 113: 470–476
Gharwan H, Groninger H (2016): Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol 13: 209–227
Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR (2016): Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375: 209–219
Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA (2016): First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2016 May 25; (5): CD010383
Gregory RK, Smith IE (2000): Vinorelbine – a clinical review. Br J Cancer 82: 1907–1913
Grgic T, Mis L, Hammond JM (2011): Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma. Ann Pharmacother 45: 78–83
Hanahan D (2014): Rethinking the war on cancer. Lancet 383: 558–563
Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ (2010): The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 9: 325-338
Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study (2005): Hydroxyurea compared with anagrelide in highrisk essential thrombocythemia. N Engl J Med 353: 33–45
Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G (2012): JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366: 787–798
Hassel JC, Heinzerling L, Aberle J, Bähr O, Eigentler TK, Grimm MO, Grünwald V, Leipe J, Reinmuth N, Tietze JK, Trojan J, Zimmer L, Gutzmer R (2017): Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treat Rev 57: 36–49
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB (2012): Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358–365
Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J (2017): Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia 31: 2398–2406
Ho GY, Woodward N, Coward JI (2016): Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Crit Rev Oncol Hematol 102: 37–46
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O‹Brien SG, Druker BJ; IRIS Investigators (2017): Longterm outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376: 917–927
Hofheinz RD, Beyer U, Al-Batran SE, Hartmann JT (2008): Mitomycin C in the treatment of gastrointestinal tumours: recent data and perspectives. Onkologie 31: 271–281
Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C (2002): Fulvestrant (ICI 182,780) is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing progressing after prior endocrine treatment. J Clin Oncol 20: 3396–3403
Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK (2004): Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22: 1605–1613
Hughes TP, Ross DM (2016): Moving treatment-free remission into mainstream clinical practice in CML. Blood 128: 17–23
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004): Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342
IQVIA Institute for Human Data Science (2018): Global oncology trends 2018. Innovation, expansion and disruption. Parsippany: IQVIA
Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists‹ Group (2010): Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int 105: 1074–1081
James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O‹Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR; STAMPEDE Investigators (2017): Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377: 338–351
Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (2014): Ovarian cancer. Lancet 384: 1376–1388
Joppi R, Gerardi C, Bertele V, Garattini S (2016): Letting post-marketing bridge the evidence gap: the case of orphan drugs. BMJ 353:i2978. doi: 10.1136/bmj.i2978
Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, Guo CC, Lotan Y, Kassouf W (2016): Bladder cancer. Lancet 388: 2796–2810
Kamisawa T, Wood LD, Itoi T, Takaori K (2016): Pancreatic cancer. Lancet 388: 73–85
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS (2017): Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376: 836–847
Khasraw M, Bell R, Dang C (2012): Epirubicin: is it like doxorubicin in breast cancer? A clinical review. Breast 21: 142–149
Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S (2015): Immuntherapie von Tumoren. Aktivierte T-Zellen als neues Behandlungsprinzip. Dtsch Arztebl 112: 809–815
Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ (2014): Non-steroidal antiandrogen monotherapy compared with luteinising hormonereleasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database Syst Rev. 2014 Jun 30;(6):CD009266
Kundranda MN, Niu J (2015): Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des Devel Ther 9: 3767–3777
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ (2010): Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693–1703
Lao J, Madani J, Puértolas T, Alvarez M, Hernández A, Pazo-Cid R, Artal A, Antón Torres A (2013): Liposomal doxorubicin in the treatment of breast cancer patients: a review. Drug Deliv 2013: 456409
Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Jurczyszyn A, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim CS, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O‹Gorman P, Terpos E, McCarthy P, Dimopoulos M, Moreau P, Orlowski RZ, Miguel JS, Anderson KC, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson PG (2016): Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia 30: 1005–1017
Lecavalier-Barsoum M, Quon H, Abdulkarim B (2014): Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev. 2014 May 15; 5: CD007104
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U (2012): Olaparib maintenance therapy in platinumsensitive relapsed ovarian cancer. N Eng J Med 366: 1382–1392
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U (2014): Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15: 852–861
Lorente D, Fizazi K, Sweeney C, de Bono JS (2015): Optimal treatment sequence for metastatic castration-resistant prostate cancer. Eur Urol Focus 2: 488–498
Macedo LT, da Costa Lima AB, Sasse AD (2012): Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer 12:89. doi: 10.1186/1471-2407-12-89
Mailankody S, Prasad V (2015): Five years of cancer drug approvals: Innovation, efficacy, and costs. JAMA Oncol 1: 539–540
Malik P, Cashen AF (2014): Decitabine in the treatment of acute myeloid leukemia in elderly patients. Cancer Manag Res 6: 53–61
Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y (2018): Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol 11: 8
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group (2015): Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372: 1909–1919
McKeage K, Wagstaff AJ (2007): Sorafenib: in advanced renal cancer. Drugs 67: 475–483
Meyerhardt JA, Mayer RJ (2005): Systemic therapy for colorectal cancer. N Engl J Med 352: 476–487
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009): Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947–957
Montero A, Fossella F, Hortobagyi G, Valero V (2005): Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6: 229–239
Moreau P, Rajkumar SV (2016): Multiple myeloma – translation of trial results into reality. Lancet 388: 111–113
Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK (2013): Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369: 722–731
Nagasawa DT, Chow F, Yew A, Kim W, Cremer N, Yang I (2012): Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg Clin N Am 23: 307–322
National Institute for Health and Clinical Excellence (NICE) (2011): Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer. Internet: guidance.nice.org.uk/TA214/Guidance/pdf/English
National Institute of Health and Clinical Excellence (2014): Prostate cancer. Diagnosis and treatment. Issued: January 2014, NICE clinical guideline 175. Internet: http://www.nice.org.uk/guidance/cg175/resources/nice-diagnosing-and-treating-prostate-cancer
Navarra P, Preziosi P (1999): Hydroxyurea: new insights on an old drug. Crit Rev Oncol Hematol 29: 249–255
O‹Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ; IRIS Investigators (2003): Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994–1004
Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A (2002): A double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant with anastrozole in post-menopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 20: 3386–3395
Palumbo A, Mina R (2013): Management of older adults with multiple myeloma. Blood Rev 27: 133–142
Pardoll DM (2012): The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252–264
Park K, Tan EH, O‹Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L (2016): Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 17: 577–589
Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N (2014): Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32: 3744–3752
Pfizer (2018): Pfizer announces overall survival results from phase 3 PALOMA-3 trial of IBRANCE® (Palbociclib) in HR+, HER2-metastatic breast cancer. Internet: https://press.pfizer.com/press-release/pfizer-announces-overallsurvival-results-phase-3-paloma-3-trial-ibrancepalbociclib-h
Pizzolato JF, Saltz LB (2003): The camptothecins. Lancet 361: 2235–2242
Postow MA, Sidlow R, Hellmann MD (2018): Immune-related adverse events associated with immune checkpoint blockade. N Eng J Med 378: 158–168
Pox C, Schmiegel W, Reinacher-Schick A (2012): Kolorektales Karzinom – Was gibt’s Neues? Dtsch med Wochenschr 137: 2577–2580
Ranpura V, Hapani S, Wu S (2011): Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305: 487–494
Raza S, Safyan, Rosenbaum E, Bowman AS, Lentzsch S (2017): Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist. Ther Adv Hematol 8: 55–70
Rajkumar SV, Kyle RA (2016) Progress in Myeloma – A monoclonal breakthrough. N Engl J Med 375: 1390–1392
Rajkumar SV, Harosseau JC (2016): Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. Blood 128: 2757–2764
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Her A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA (2015a): Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372: 320–330
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators (2015b): Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372: 2521–2532
Roberts K, Culleton V, Lwin Z, O‹Byrne K, Hughes BG (2017): Immune checkpoint inhibitors: navigating a new paradigm of treatment toxicities. Asia Pac J Clin Oncol 13: 277–288
Robertson JF, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ (2016): Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 388: 2997–3005
Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, Lindemann J, Ellis MJ (2009): Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 27: 4530–4535
Rosario DJ, Davey P, Green J, Greene D, Turner B, Payne H, Kirby M (2016): The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK. World J Urol 34: 1601–1609
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators (2013): Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368: 138–148
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators (2015): Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16: 152–160
San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M (2013): Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, openlabel, phase 3 trial. Lancet Oncol 14: 1055–1066
San Miguel J (2015): Introduction to a series of reviews on multiple myeloma. Blood 125: 3039–3040
Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J (2008): Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013–2019
Sartor O, de Bono JS (2018): Metastatic prostate cancer. N Eng J Med 378: 645–657
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators (2012): Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367: 1187–1197
Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J (2014): Mercaptopurine/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol 36: 503–517
Scott AM, Wolchok JD, Old LJ (2012): Antibody therapy of cancer. Nat Rev Cancer 12: 278–287
Shankland KR, Armitage JO, Hancock BW (2012): Non-Hodgkin lymphoma. Lancet 380: 848–857
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O‹Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA (2013): Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368: 2385–2394
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group (2005): Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132
Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AK (2018): Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol 36: 728–734
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001): Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792
Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF (2012): Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30: 2055–2062
Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O‹Reilly EM, Uronis HE, Ramanathan RK, Crane CH, Engebretson A, Ruggiero JT, Copur MS, Lau M, Urba S, Laheru D (2016): Metastatic pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34: 2784–2796
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators (2014): First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371: 2167–2177
Stilgenbauer S, Hallek M (2013): Chronische lymphatische Leukämie. Therapie und genetisches Risikoprofil. Internist 54: 164–170
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005): Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987–996
Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J (2013): Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14: 461–471
Thompson PA, Kantarjian HM, Cortes JE (2015): Diagnosis and treatment of chronic myeloid leukemia in 2015. Mayo Clin Proc 90: 1440–1454
Tomasini P, Barlesi F, Mascaux C, Greillier L (2016): Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes. Ther Adv Med Oncol 8: 198–208
Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F (2011): Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011–2019
Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007): Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658–1664
Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C (2012): Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30: 3499–3506
Van Dalen EC, van der Pal HJ, Kremer LC (2016): Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2016 Mar 3;3:CD005008. doi: 10.1002/14651858.cd005008.pub4
Van de Donk NWCJ, Moreau P, Plesner T, Palumbo A, Gay F, Laubach JP, Malavasi F, Avet-Loiseau H, Mareos M-V, Sonneveld P, Lokhorst HM, Richardson PG (2016): Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood 127: 681–695
Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S (2015): Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372: 426–435
Varga C, Maglio M, Ghobrial IM, Richardson PG (2018): Current use of monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol 181: 447–459
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study Group (2012): Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367: 1783–1791
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012): A doubleblind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366: 799–807
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013): Cancer genome landscapes. Science 339: 1546–1558
Weeraratna AT (2012): RAF around the edges – the paradox of BRAF inhibitors. N Engl J Med 366: 271–273
Wagner AD, Thomssen C, Haerting J, Unverzagt S (2012): Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst Rev. 2012 Jul 11; 7: CD008941
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA (2013): Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369: 507–516
Wang Y, Yang F, Shen Y, Zhang W, Wang J, Chang VT, Andersson BS, Qazilbash MH, Champlin RE, Berenson JR, Guan X, Wang ML (2016): Maintenance therapy with immunomodulatory drugs in multiple myeloma: A meta-analysis and systematic review. J Natl Cancer Inst 108: 1–10
Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M; NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society (2012): Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13: 707–715
Wilson RAM, Evans TRJ, Fraser AR, Nibbs RJB (2017): Immune checkpoint inhibitors: new strategies to checkmate cancer. Clin Exp Immunol 191: 133–148
Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O’Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV (2015): Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16: 141–151
Young RM, Staudt LM (2013): Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 12: 229–243
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C (2011): Erlotinib versus chemotherapy as firstline treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735–742
Zolot RS, Basu S, Million RP (2013): Antibody-drug conjugates. Nat Rev Drug Discov 12: 259–260
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Ludwig, WD., Schwabe, U. (2018). Onkologika. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2018. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57386-0_37
Download citation
DOI: https://doi.org/10.1007/978-3-662-57386-0_37
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-57385-3
Online ISBN: 978-3-662-57386-0
eBook Packages: Medicine (German Language)